Neoantigen Cancer Vaccine Market Will Touch USD 1,322.8 Million by 2030

According to P&S Intelligence, the global neoantigen cancer vaccine market was valued at USD 24.4 million in 2022, and it will advance at a mammoth 67.6% compound annual growth rate, to touch USD 1,322.8 million, by 2030.

The key factor boosting the advancement of the industry include the mounting incidence of cancer and surging research activities all over the world. Moreover, because of the growing importance of personalized treatments of cancer, pharmaceutical companies are focusing on R&D to meet the existing and possible requirements for neoantigen cancer vaccines.

Browse detailed report on this report: https://www.psmarketresearch.com/market-analysis/neoantigen-cancer-vaccine-market

Based on product type, the personalized category accounted for the largest share, of 70%, in 2022. Developing personalized cancer vaccines need suitable antigen screening in specific patients. The exceptional potential of personalized neoantigens to induce long-lasting tumor-specific memory T-cell populations has resulted in the mounting utilization of such drugs for effective cancer treatment, therefore boosting the advancement of this category.

In 2022, the nucleic acid category, based on type, accounted for the largest neoantigen cancer vaccine market share, of 55%. This can be attributed to the increasing number of drug manufacturers actively involved in producing advanced and effective nucleic acid-based vaccines.

In 2022, the lung cancer category, based on therapeutic specialty, accounted for the largest share, of 30%. This can be attributed to the higher prevalence of lung cancer particularly in Ireland, New Zealand, the U.S., and Australia, as a result of the surging smoking population. Moreover, one of the main causes of lung cancer all over the world is smoking.

Whereas, the liver cancer category, accounted for a significant share of the industry, in 2022. As per the World Health Organization, in 2022, the liver, lungs, and colon are the major causes of cancer deaths. Where liver cancer is the third-leading cause of cancer death all over the world.

Some of the Key Players in the Market Are:
• Moderna Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca plc
• Agenus Inc.
• OSE Immunotherapeutics
• Advaxis Inc.
• Medigene AG
• Neon Therapeutics
• Genocea Biosciences
• Immunovative Therapies Ltd.
• Gritstone bio

North America accounted for the largest share in 2022, and this trend will continue in the years to come. This is attributed to the surging incidence of different cancers and speedy innovation in the healthcare sector. Moreover, the increasing R&D activities will boost the regional industry, through the approval and production of new therapeutics in the years to come.

Download sample pages of this report: https://www.psmarketresearch.com/market-analysis/neoantigen-cancer-vaccine-market/report-sample

Additionally, the surging prevalence of pancreatic adenocarcinoma has resulted in the invention of new neoantigen therapies by biotechnology manufacturers, therefore boosting the progression of the industry in North America.

The APAC neoantigen cancer vaccine industry will witness the fastest growth in the coming years. This is primarily credited to the speedy upgradation in targeted immunotherapy, as a result of the surging number of research initiatives in the regional nations, mainly due to the increasing cases of cancer.

With the surging research activities, as well as the increasing prevalence of cancer all over the world, the neoantigen cancer vaccine industry will continue to advance in the years to come.

Market Size Breakdown by Segment

By Product Type
• Personalized
• Off-the-Shelf
By Type
• Nucleic Acid
o DNA
o RNA
• Peptide
• Dendritic-Cell-Based
By Therapeutic Specialty
• Lung Cancer
• Urinary System Cancer
• Melanoma
• Liver Cancer
• Head and Neck Cancer
• Blood and Bone Marrow Cancer
By End User
• Hospitals & Clinics
Regional Analysis
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
• Asia-Pacific
o Japan
o China
o India
o South Korea
o Australia
• Latin America
o Brazil
o Mexico
• Middle East and Africa
o Saudi Arabia
o South Africa
o U.A.E.

Contact:
Chandra Mohan
AVP - Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Blog: https://healthcarefuturetrends.blogspot.com

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

This release was published on openPR.